清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies

医学 PCSK9 随机对照试验 内科学 临床试验 前蛋白转化酶 随机化 临床研究阶段 相(物质) 胃肠病学 可欣 口服 Evolocumab公司 梅德林
作者
Alberico Luigi Catapano,Elina Mikhailova,Ann Marie Návar,Puja Banka,Pablo Corral,Manish Saxena,Philippe Gabríel Steg,Subodh Verma,Andrew Kordahi,Geraldine Mendizabal,Pengfei Zhu,Christie Mitchell Ballantyne,Chau-Chung Wu,Chii‐Min Hwu,Kai‐Chien Yang,Ping-Yen Liu,Kuo-Chun Hung,Sybil Charrière,Bertrand Cariou,Philippe Gabríel Steg
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:88 (3): 340-352 被引量:31
标识
DOI:10.1016/j.jacc.2026.03.036
摘要

BACKGROUND: Many adults fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals on statin monotherapy, requiring additional nonstatin lipid-lowering medication. Enlicitide, an oral proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor, lowered LDL-C by 60% compared with placebo; its efficacy compared with other oral nonstatin therapies has yet to be examined. OBJECTIVES: This study assessed the efficacy of enlicitide, a novel oral PCSK9 inhibitor, vs other oral nonstatin therapies. METHODS: In this phase 3, randomized, double-blind, active-comparator trial, statin-treated adults aged ≥18 years with LDL-C ≥55 mg/dL and a previous major atherosclerotic cardiovascular disease (ASCVD) event, or LDL-C ≥70 mg/dL if at intermediate to high risk for a first event, were randomized in 2:1:1:2 fashion to 20 mg enlicitide (n = 101), 180 mg bempedoic acid (n = 50), 10 mg ezetimibe (n = 50), or 180 mg bempedoic acid plus 10 mg ezetimibe (n = 100) once daily for 56 days. The primary endpoint was mean percentage change in LDL-C from baseline to day 56; secondary endpoints included mean percentage changes in apolipoprotein B (ApoB) and non-high-density lipoprotein cholesterol (nonHDL-C). Safety endpoints included overall adverse events (AEs) and discontinuations due to AEs. RESULTS: Among 301 randomized participants (mean age 64.4 years, 37% female, 98% receiving moderate- to high-intensity statin), 298 (99.0%) completed the trial. The mean percentage change in LDL-C from baseline to day 56 was -64.6% (95% CI: -68.3% to -60.9%) with enlicitide, -6.3% (95% CI: -13.5% to 0.8%) with bempedoic acid, -27.8% (95% CI: -32.3% to -23.4%) with ezetimibe, and -36.5% (95% CI: -40.8% to -32.2%) with bempedoic acid plus ezetimibe; enlicitide was superior to each comparator (all P < 0.001). Reductions in ApoB and nonHDL-C were also greater with enlicitide (all P < 0.001). Proportions of participants with AEs and discontinuations due to AEs were similar across treatment arms. CONCLUSIONS: In statin-treated adults with a history of a major ASCVD event or at increased risk for a first event, enlicitide achieved greater reductions in LDL-C, ApoB, and nonHDL-C than other oral nonstatin therapies, demonstrating its potential role as an important add-on option when LDL-C goals are not met with the use of statins alone. (A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate [MK-0616, Oral PCSK9 Inhibitor] Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia [MK-0616-018] [CORALreef AddOn; NCT06450366).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
如意的醉蓝完成签到,获得积分10
1秒前
6秒前
8秒前
miaorunquan完成签到,获得积分0
9秒前
黄景滨完成签到 ,获得积分10
12秒前
ymmmaomao23完成签到,获得积分10
13秒前
阔达的芹菜完成签到,获得积分10
13秒前
自觉的孤兰完成签到,获得积分10
17秒前
诺亚方舟哇哈哈完成签到 ,获得积分0
20秒前
29秒前
小红书求接接接接一篇完成签到,获得积分10
35秒前
系统昵称完成签到,获得积分10
35秒前
朴实乐天完成签到,获得积分10
46秒前
HelloBOB完成签到 ,获得积分10
47秒前
53秒前
俭朴竺完成签到,获得积分10
59秒前
liangyao完成签到,获得积分20
1分钟前
Tardes关注了科研通微信公众号
1分钟前
1分钟前
朴实惜寒完成签到,获得积分10
1分钟前
11完成签到 ,获得积分10
1分钟前
1分钟前
king完成签到 ,获得积分10
1分钟前
wsj完成签到 ,获得积分10
1分钟前
Tardes发布了新的文献求助10
1分钟前
ss完成签到,获得积分10
1分钟前
甜美的梦芝完成签到,获得积分10
1分钟前
西瓜柠檬可乐完成签到 ,获得积分10
1分钟前
李煜琛完成签到 ,获得积分10
1分钟前
悦耳的竺完成签到 ,获得积分10
1分钟前
搜集达人的应助被冲冲冲采纳,获得10
1分钟前
大力的安阳完成签到 ,获得积分10
1分钟前
无花果的应助被ZLPY采纳,获得30
1分钟前
2分钟前
2分钟前
刘亚梅完成签到 ,获得积分10
2分钟前
醉熏的小凡完成签到,获得积分10
2分钟前
冲冲冲发布了新的文献求助10
2分钟前
apt完成签到 ,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780536
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697